David Swoboda, MD
Hematology & Oncology · Tampa, FLNPI 1952729741
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by GSK at 31.2% of the total. 2025 is the largest year on record at $44,762, more than ten times the $596 reported in 2019. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $540.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$35K
- E.r. Squibb & Sons, L.L.C.$23K
- Servier Pharmaceuticals LLC$21K
- Syndax Pharmaceuticals, Inc.$7K
- Daiichi Sankyo Inc.$5K
- Bristol Myers Squibb$5K
- plus $16K from 34 others
Across 261 payments — averaging $2340.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$294K
- Trillium Therapeutics USA, LLC$98K
- Syndax Pharmaceuticals, Inc.$97K
- Beigene, Ltd.$87K
- Beone Medicines USA, Inc.$18K
- Beigene USA, Inc.$9K
- plus $8K from 1 others
What the payments were for
- Consulting fees$43,50239%
- Speaking & faculty fees$49,80244%
- Travel & lodging$9,1898%
- Food & beverage$10,1169%
- Education$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,873 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 21 | $673,755 |
| XospataGilteritinib Fumarate | 28 | $595,612 |
| TibsovoIvosidenib | 12 | $395,144 |
| ScemblixAsciminib Hydrochloride | 18 | $375,992 |
| VenclextaVenetoclax | 97 | $375,864 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $366,350 |
| IclusigPonatinib Hcl | 15 | $302,261 |
| PromactaEltrombopag Olamine | 12 | $279,308 |
| JakafiRuxolitinib Phosphate | 15 | $244,410 |
| VanflytaQuizartinib Dihydrochloride | 17 | $230,581 |
| SprycelDasatinib | 13 | $214,528 |
| CresembaIsavuconazonium Sulfate | 19 | $110,063 |
| Hydroxyurea | 25 | $530 |
| Acyclovir | 26 | $204 |
| Prochlorperazine Maleate | 14 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXospata, Cresemba | $3,330 | $705,67647 claims |
| Bristol Myers SquibbIdhifa | $5,250 | $673,75521 claims |
| NovartisScemblix, Promacta | $338 | $655,30130 claims |
| Servier Pharmaceuticals LLCTibsovo | $20,727 | $395,14412 claims |
| AbbVieVenclexta | $2,604 | $375,86497 claims |
| GSKOjjaara | $35,232 | $366,35014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $103 | $302,26115 claims |
| Incyte CorporationJakafi | $137 | $244,41015 claims |
| Daiichi Sankyo Inc.Vanflyta | $5,349 | $230,58117 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $23,351 | $214,52813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.